Association Between Common Vaginal Infections and Cervical Non-Human Papillomavirus (HPV) 16/18 Infection in HPV-Vaccinated Women.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
13 02 2021
Historique:
received: 01 04 2020
accepted: 27 06 2020
pubmed: 3 7 2020
medline: 1 10 2021
entrez: 3 7 2020
Statut: ppublish

Résumé

How vaginal infections such as bacterial vaginosis, Candida spp, and Trichomonas vaginalis affect persistence of human papillomavirus (HPV) infection is not well established. Our study aimed to evaluate the association between common vaginal infections and cervical non-HPV16/18 infection, as risk factors associated with persistence of nonvaccine HPV types will become increasingly relevant in the setting of HPV vaccination. We performed an analysis in 2039 AS04-HPV16/18-vaccinated women enrolled in a phase II/III trial in China, who were HPV DNA negative at month 0 and 6 and had at least 1 subsequent follow-up visit. Vaginal infections were detected in liquid-based cytology according to the diagnostic criteria of the Bethesda System. Associations between vaginal infections and incident and 6-month persistent non-HPV16/18 infections in the cervix were evaluated using generalized estimating equations, adjusting for the age at initial vaccination, as well as HPV types in the persistence analysis. Study visits with any vaginal infection had a statistically significant increased risk of incident non-HPV16/18 infection compared to those without vaginal infections (odds ratio [OR], 1.44 [95% confidence interval {CI}, 1.09-1.92]). However, vaginal infections were not associated with 6-month persistent non-HPV16/18 infection (OR, 1.02 [95% CI, .62-1.69]). Our study suggests that common vaginal infections are not associated with persistence of non-HPV16/18 infection among HPV16/18-vaccinated women.

Sections du résumé

BACKGROUND
How vaginal infections such as bacterial vaginosis, Candida spp, and Trichomonas vaginalis affect persistence of human papillomavirus (HPV) infection is not well established. Our study aimed to evaluate the association between common vaginal infections and cervical non-HPV16/18 infection, as risk factors associated with persistence of nonvaccine HPV types will become increasingly relevant in the setting of HPV vaccination.
METHODS
We performed an analysis in 2039 AS04-HPV16/18-vaccinated women enrolled in a phase II/III trial in China, who were HPV DNA negative at month 0 and 6 and had at least 1 subsequent follow-up visit. Vaginal infections were detected in liquid-based cytology according to the diagnostic criteria of the Bethesda System. Associations between vaginal infections and incident and 6-month persistent non-HPV16/18 infections in the cervix were evaluated using generalized estimating equations, adjusting for the age at initial vaccination, as well as HPV types in the persistence analysis.
RESULTS
Study visits with any vaginal infection had a statistically significant increased risk of incident non-HPV16/18 infection compared to those without vaginal infections (odds ratio [OR], 1.44 [95% confidence interval {CI}, 1.09-1.92]). However, vaginal infections were not associated with 6-month persistent non-HPV16/18 infection (OR, 1.02 [95% CI, .62-1.69]).
CONCLUSIONS
Our study suggests that common vaginal infections are not associated with persistence of non-HPV16/18 infection among HPV16/18-vaccinated women.

Identifiants

pubmed: 32614401
pii: 5866538
doi: 10.1093/infdis/jiaa384
pmc: PMC7982446
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

445-451

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

J Natl Cancer Inst. 2020 Oct 1;112(10):1038-1046
pubmed: 32091594
J Clin Microbiol. 2012 Feb;50(2):300-6
pubmed: 22162556
Sex Transm Infect. 2011 Aug;87(5):366-7
pubmed: 21685188
Am Fam Physician. 2018 Mar 1;97(5):321-329
pubmed: 29671516
Sex Transm Infect. 2011 Aug;87(5):372-6
pubmed: 21471141
Int J Cancer. 2014 Dec 1;135(11):2604-11
pubmed: 24740547
Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):699-707
pubmed: 21173170
Cancer Med. 2019 Oct;8(14):6195-6211
pubmed: 31305011
Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1021-7
pubmed: 11588127
Clin Ther. 2014 Jan 1;36(1):38-45
pubmed: 24417784
Microbiome. 2016 Nov 1;4(1):58
pubmed: 27802830
Gynecol Obstet Invest. 2010;70(4):273-80
pubmed: 21051847
J Natl Cancer Inst. 2010 Dec 1;102(23):1794-804
pubmed: 21098758
J Infect Dis. 2005 Apr 1;191(7):1129-39
pubmed: 15747249
Am J Epidemiol. 2005 Oct 1;162(7):668-75
pubmed: 16120706
Clin Ther. 2016 Dec;38(12):2567-2577
pubmed: 27836494
Sci Rep. 2017 Aug 31;7(1):10200
pubmed: 28860468
Acta Oncol. 2000;39(1):71-5
pubmed: 10752657
BMC Infect Dis. 2009 Feb 12;9:16
pubmed: 19216747
PLoS One. 2017 May 22;12(5):e0178033
pubmed: 28531212
Glob J Health Sci. 2014 Oct 29;7(3):8-14
pubmed: 25948431
Asian Pac J Cancer Prev. ;18(5):1289-1292
pubmed: 28610416
Cancer. 2007 Oct 25;111(5):269-74
pubmed: 17823916
Sex Transm Infect. 2014 Nov;90(7):550-5
pubmed: 24728044
Front Oncol. 2020 Apr 07;10:449
pubmed: 32318343
PLoS One. 2013 Dec 30;8(12):e86266
pubmed: 24386492
J Clin Virol. 2018 Feb - Mar;99-100:84-90
pubmed: 29396352
Int J Cancer. 2005 Aug 10;116(1):110-5
pubmed: 15756673
Diagn Cytopathol. 2005 Jun;32(6):341-4
pubmed: 15880709
PLoS One. 2012;7(10):e45201
pubmed: 23056195
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:2-13
pubmed: 28964706
Int J Public Health. 2019 Jul;64(6):943-955
pubmed: 31175391
J Clin Virol. 2017 Feb;87:43-48
pubmed: 27992790
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5258-65
pubmed: 7777494
APMIS. 2007 Jul;115(7):809-13
pubmed: 17614847
Int J Cancer. 2004 Sep 1;111(3):431-9
pubmed: 15221973
Sex Transm Dis. 2003 Jul;30(7):575-80
pubmed: 12838087
Cochrane Database Syst Rev. 2018 May 09;5:CD009069
pubmed: 29740819

Auteurs

Shang-Ying Hu (SY)

Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Sabrina H Tsang (SH)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Feng Chen (F)

Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Qin-Jing Pan (QJ)

Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Wen-Hua Zhang (WH)

Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Ying Hong (Y)

Department of Obstetrics and Gynecology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.

Joshua N Sampson (JN)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Allan Hildesheim (A)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Fang-Hui Zhao (FH)

Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Aimée R Kreimer (AR)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH